Sample-Size Formula for the Proportional-Hazards Regression Model
1983/06/01 by David A. Schoenfeld, David Schoenfeld · 30 citations
Mathematics · Computer Science · #Statistical Methods in Clinical Trials #Statistical Methods and Inference #Bayesian Methods and Mixture Models
paper · doi:10.2307/2531021
Abstract
A formula is derived for determining the number of observations necessary to test the equality of two survival distributions when concomitant information is incorporated. This formula should be useful in designing clinical trials with a heterogeneous patient population. Schoenfeld (1981, Biometrika 68, 316-319) derived the asymptotic power of a class of statistics used to test the equality of two survival distributions. That result is extended to the case where concomitant information is available for each individual and where the proportional-hazards model holds. The loss of efficiency caused by ignoring concomitant variables is also computed.
Cited by
- Blinded‐Into‐Unblinded Interim Analyses for Clinical Trials With Time‐to‐Event Endpoints
- A comparative overview of win ratio and joint frailty models for recurrent event endpoints with applications in oncology and cardiology
- Toward Valid Generative Clinical Trial Data with Survival Endpoints
- Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial
- Design aspects of COVID-19 treatment trials: Improving probability and time of favourable events
- Randomised trial of proton vs. carbon ion radiation therapy in patients with chordoma of the skull base, clinical phase III study HIT-1-Study. [europepmc]
- Analysis and design of randomised clinical trials involving competing risks endpoints. [europepmc]
- Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. [europepmc]
- The Nicoya region of Costa Rica: a high longevity island for elderly males. [europepmc]
- Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data. [europepmc]
- Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. [europepmc]
- Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study. [europepmc]
- The Impact of Blood Transfusion on Recurrence and Mortality Following Colorectal Cancer Resection: A Propensity Score Analysis of 4,030 Patients. [europepmc]
- RhoGAP domain-containing fusions and PPAPDC1A fusions are recurrent and prognostic in diffuse gastric cancer. [europepmc]
- A 23-year study of mortality and development of co-morbidities in patients with obesity undergoing bariatric surgery (laparoscopic gastric banding) in comparison with medical treatment of obesity. [europepmc]
- Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression. [europepmc]
- Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults : BMI change and the risks of colorectal cancer incidence and mortality. [europepmc]
- Prediction and clinical utility of a contralateral breast cancer risk model. [europepmc]
- Association of Deceased Donor Acute Kidney Injury With Recipient Graft Survival. [europepmc]
- Incidence of Diabetic Foot Ulcer and Its Predictors Among Diabetes Mellitus Patients at Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia: A Retrospective Follow-Up Study. [europepmc]
- Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. [europepmc]
- Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. [europepmc]
- Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. [europepmc]
- Age-Related Differences in the Role of Risk Factors for Ischemic Stroke. [europepmc]
- Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. [europepmc]
- Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. [europepmc]
- Assessment of Parafoveal Diabetic Macular Ischemia on Optical Coherence Tomography Angiography Images to Predict Diabetic Retinal Disease Progression and Visual Acuity Deterioration. [europepmc]
- Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer. [europepmc]
- Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 + B cell tumors: a phase 1/2 trial. [europepmc]
- Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial. [europepmc]
Related